Celsion Corporation

392 articles with Celsion Corporation

• Celsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. Handke

  7/15/2021

  Celsion Corporation today announced the addition of Dan H. Barouch, M.D., Ph.D and Luke D. Handke, Ph.D. to its Vaccine Advisory Board.

• Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®

  6/23/2021

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox®, the Company’s proprietary heat-activated liposomal encapsulation of doxorubicin.

• Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank

  6/21/2021

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces it has entered into a $10 million loan facility with Silicon Valley Bank.

• Celsion Appoints Christine A. Pellizzari to its Board of Directors

  6/9/2021

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announced the appointment of Christine A. Pellizzari to the Celsion Board of Directors, effective June 8, 2021.

• Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors

  6/8/2021

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. to its Board of Directors, effective June 4, 2021.

• Celsion Corporation Announces Adjournment Of Annual Meeting - June 07, 2021

  6/7/2021

  Celsion Corporation announced that its 2021 Annual Meeting of Stockholders, originally scheduled for Friday, June 4, 2021 at 10:00 a.m., and adjourned to Friday, June 4, 2021 at 4:00 p.m., was convened and adjourned without any business being conducted due to a quorum not being present to conduct the meeting.

• CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

  6/4/2021

  Celsion Corporation announced that its 2021 Annual Meeting of Stockholders, originally scheduled for today, Friday, June 4, 2021 at 10:00 a.m., was adjourned and reconvened to 4:00 p.m. today, Friday, June 4, 2021, due to lack of the required quorum.

• Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses

  5/11/2021

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announced it has received $1.85 million in net cash proceeds from the sale of approximately $2.0 million of its unused New Jersey net operating losses.

• Celsion Management Participates in Alliance Global Partners Virtual Series

  4/22/2021

  Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management participated in Alliance Global Partners’ (AGP) Virtual Series on April 21, 2021. Michael H. Tardugno, Chairman, President and Chief Executive Officer, and Kursheed Anwar, Ph.D., Executive Vice President and Chief Scientific Officer were interviewed in a “Fireside Chat”

• CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING

  4/5/2021

  Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net proceeds of $13.9 million, after deducting placement agents' fees but before expenses payable by the Company.

• Celsion Corporation Announces $15 Million Registered Direct Offering - Mar 31, 2021

  3/31/2021

  Celsion Corporation, announced it has entered into definitive agreements with institutional investors for the purchase and sale of 11,538,462 shares of its common stock at a purchase price of $1.30 per share in a registered direct offering, for gross proceeds of $15 million before deducting placement agent fees and expenses.

• Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021

  3/12/2021

  Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. EDT on Friday, March 19, 2021 to discuss financial results for the year ended December 31, 2020 and provide an update on clinical development programs with GEN-1, a DNA-based immunotherapy for the localized treatment of ovaria

• Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer

  10/24/2018

  Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced results from its dose escalating Phase IB OVATION I trial evaluating neoadjuvant chemotherapy (NAC) treatment for six cycles and GEN-1 given weekly for a total of eight doses prior to interval debulking surgery in newly diagnosed patients with Stage III/IV ovarian cancer.

• Celsion Announces ThermoDox HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting

  2/12/2018

  ThermoDox is Celsion’s proprietary, heat-activated liposomal encapsulation of doxorubicin for the treatment of primary liver cancer.

• Celsion Corporation Provides Corporate Update and 2018 Outlook

  1/18/2018

  A look at what's in store for Celsion this year.

• Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer

  1/4/2018

  The Phase I/II trial was developed with extensive input from the Company’s Medical Advisory Board.

• Celsion Announces Publication of the Study of ThermoDox + Ultrasound, “TARDOX Study Protocol” in the Journal of Therapeutic Ultrasound

  11/20/2017

  The article describes the clinical trial design for the TARDOX Study.

• Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

  11/14/2017

  The Phase I/II study builds on the highly promising clinical and translational research data for the recently completed Phase IB dose-escalating OVATION Study.

• Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update

  11/14/2017

  For the quarter ended September 30, 2017, Celsion reported a net loss of $5.7 million, or $(0.70) per share, compared to a net loss of $6.4 million, or $(3.22) per share, in the same period of 2016

• Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017

  11/7/2017

  The call will be archived for replay on Tuesday, November 14, 2017 and will remain available until Tuesday, November 28, 2017.